This is an AI-generated summary created from the transcript of the Ripple conversation led by the hosts listed on this page and recorded at The Drop on September 17, 2025.

The Ripple brought founders, investors, and scientists together to unpack what’s blocking scale-up in industrial biotech.

People shared lessons on how past ventures failed for all sorts of reasons: tech limits, over-optimism, tough economics, and complexity around scaling.

Big takeaways were:

• You need to pick the right molecule and watch costs from day one.

• Teams with hands-on, real-world experience matter a lot.

• Building and keeping strong partnerships helps you grow and tackle problems.

• Investors want to see solid numbers and a clear business case, not just hope.

• Talking to customers early and often beats waiting for that “perfect” product.

The group agreed: successful scaling isn’t just about clever ideas or cash. It’s really about nailing the basics, learning as you go, and staying open to new ways to work together in a tough market.